iCell for Drug Screening & Development

Drug Development: A Complex and Expensive Journey

Launching a new drug typically demands a decade of effort and a staggering investment of over $1 billion. The path is riddled with risks, with a high likelihood of failure looming over every step.

iPSC Technology: A Bridge to Success

The rise of iPSC technology offers a beacon of hope. It promises to boost the success rate in drug development by bridging the gap left by traditional cell and animal models. These models often fall short in accurately reflecting human phenotypes due to inherent species differences.

iCells International Products: Advancing Drug Development Strategies

Our iCells products encompass a spectrum of terminally-differentiated cells derived from human iPS cells. They are crafted to tackle the multifaceted challenges in drug development, particularly by streamlining stages within the pharmaceutical pipeline. This includes crafting disease models that closely mimic the human body, thereby deepening our pharmaceutical understanding of a range of diseases and pinpointing the most promising drug candidates.